Home › Research › Disease mechanisms
Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer's Disease
Wu L, Xian X, Xu G, Tan Z, Dong F, Zhang M, Zhang F.. Mediators of inflammation, 2022-08-21
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) is a progressive neurodegenerative disease that primarily manifests as memory deficits and cognitive impairment and has created health challenges for patients and society. In AD, amyloid β -protein (A β ) induces Toll-like receptor 4 (TLR4) activation in microglia. Activation of TLR4 induces downstream signaling pathways and promotes the generation of proinflammatory cytokines, such as tumor necrosis factor- α (TNF- α ), interleukin-6 (IL-6), and interleukin-1 β (IL-1 β ), which also trigger the activation of astrocytes and influence amyloid-dependent neuronal death. Therefore, TLR4 may be an important molecular target for treating AD by regulating neuroinflammation. Moreover, TLR4 regulates apoptosis, autophagy, and gut microbiota and is closely related to AD. This article reviews the role of TLR4 in the pathogenesis of AD and a range of potential therapies targeting TLR4 for AD. Elucidating the regulatory mechanism of TLR4 in AD may provide valuable clues for developing new therapeutic strategies for AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wu, L., Xian, X., Xu, G., Tan, Z., Dong, F., Zhang, M., et al. (2022). Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer's Disease. Mediators of inflammation. https://doi.org/10.1155/2022/7924199
Vancouver
Wu L, Xian X, Xu G, Tan Z, Dong F, Zhang M, et al. Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer's Disease. Mediators of inflammation. 2022. doi:10.1155/2022/7924199. PMID: 36046763.
BibTeX
@article{wu2022-36046763,
author = {Wu, L. and Xian, X. and Xu, G. and Tan, Z. and Dong, F. and Zhang, M. and Zhang, F.},
title = {{Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer's Disease}},
journal = {Mediators of inflammation},
year = {2022},
doi = {10.1155/2022/7924199},
pmid = {36046763},
url = {https://doi.org/10.1155/2022/7924199}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Activation of TLR4 induces downstream signaling pathways and promotes the generation of proinflammatory cytokines, such as tumor necrosis factor- α (TNF- α ), interleukin-6 (IL-6), and interleukin-1 β (IL-1 β ), which also trigger the activation of astrocytes and influence amyloid-dependent neuronal death.
- Therefore, TLR4 may be an important molecular target for treating AD by regulating neuroinflammation.
- Moreover, TLR4 regulates apoptosis, autophagy, and gut microbiota and is closely related to AD.
- This article reviews the role of TLR4 in the pathogenesis of AD and a range of potential therapies targeting TLR4 for AD.
- Elucidating the regulatory mechanism of TLR4 in AD may provide valuable clues for developing new therapeutic strategies for AD.
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 25 of the 58 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Mediators of inflammation) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36046763) |
| Free to read | 2 / 2 | Free to read |
| Points | 25 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 25 of the 58 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.